Repository logo
 
Publication

Peptide Receptor Radionuclide Therapy with 177 Lu-DOTA-TATE As a Promising Treatment of Malignant Insulinoma: a Series of Case Reports and Literature Review

2019Journal article Open access
Simple item page
dc.contributor.authorMagalhães, D
dc.contributor.authorSampaio, I
dc.contributor.authorFerreira, G
dc.contributor.authorBogalho, P
dc.contributor.authorMartins-Branco, D
dc.contributor.authorSantos, R
dc.contributor.authorDuarte, H
dc.date.accessioned2022-08-26T14:24:41Z
dc.date.available2022-08-26T14:24:41Z
dc.date.issued2019
dc.description.abstractIntroduction: Insulinomas are a rare type of pancreatic neuroendocrine tumours characterized by insulin hypersecretion. They are considered malignant when metastases are present. Traditional therapies often promote only temporarily symptomatic relief and may be associated with severe adverse effects. There is scarce experience in treating malignant insulinomas with peptide receptors radionuclide therapy (PRRNT). Patients and methods: We describe PRRNT results in four patients with inoperable malignant insulinomas with poorly controllable hypoglycaemia. All patients received therapy with 177Lu-DOTA-TATE after conventional therapies failed in controlling disease progression and symptoms. The activity administered per cycle was 4.8-7.4 GBq. The interval between cycles was 10-16 weeks. Haematology, liver and kidney function tests were performed before treatment initiation and 5 and 10 weeks after each cycle. Results: Patient 1 presented significant clinical benefit for 13 months after PRRNT, with imaging improvement. Patient 2 obtained reduction of the number and severity of hypoglycaemic episodes during 15 months after therapy. Patient 3 is asymptomatic since PRRNT first cycle performed 23 months ago and revealed significant imaging improvement. Patient 4 had resolution of hypoglycaemia only 3 days after PRRNT first cycle and today, 16 months after therapy, the disease seems to be in remission and the patient maintains euglycaemic state. PRRNT was well tolerated, with only hematologic grade 2 toxicity in patient 1 and mild kidney toxicity in patient 3. Conclusions: After the start of 177Lu-DOTA-TATE all patients achieved hypoglycaemia symptomatic control and had evident improvement of their quality of life. Three patients showed imagiological improvement suggesting reduced tumour load.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Endocrinol Invest. 2019 Mar;42(3):249-260.pt_PT
dc.identifier.doi10.1007/s40618-018-0911-3.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4234
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringerpt_PT
dc.subjectHCC ENDpt_PT
dc.subjectAgedpt_PT
dc.subjectFemalept_PT
dc.subjectHumanspt_PT
dc.subjectMiddle Agedpt_PT
dc.subjectInsulinoma / metabolismpt_PT
dc.subjectInsulinoma / pathologypt_PT
dc.subjectInsulinoma / radiotherapy*pt_PT
dc.subjectNeuroendocrine Tumors / metabolismpt_PT
dc.subjectNeuroendocrine Tumors / pathologypt_PT
dc.subjectNeuroendocrine Tumors / radiotherapy*pt_PT
dc.subjectOctreotide / analogs & derivatives*pt_PT
dc.subjectOctreotide / therapeutic usept_PT
dc.subjectOrganometallic Compounds / therapeutic use*pt_PT
dc.subjectReceptors, Peptide / metabolism*pt_PT
dc.subjectRetrospective Studiespt_PT
dc.subjectTreatment Outcomept_PT
dc.titlePeptide Receptor Radionuclide Therapy with 177 Lu-DOTA-TATE As a Promising Treatment of Malignant Insulinoma: a Series of Case Reports and Literature Reviewpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage260pt_PT
oaire.citation.startPage249pt_PT
oaire.citation.titleJournal of Endocrinological Investigationpt_PT
oaire.citation.volume42pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
J Endocrinol Invest 2019 249.pdf
Size:
1.09 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

END - Artigos